MTAP欠失を伴う進行性または転移性固形腫瘍の成人患者におけるS095035の単剤および併用療法

基本情報

NCT ID

NCT06188702

ステータス

募集中

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

342

治験依頼者名

Servier

概要

This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)